Prognostic value of total tumour volume, adding necrosis to metabolic tumour volume, in advanced or metastatic non-small cell lung cancer treated with first-line pembrolizumab.
Auteurs : Eude F, Guisier F, Salaün M, Thiberville L, Pressat-Laffouilhere T, Vera P, Decazes P. Prognostic value of total tumour volume, adding necrosis to metabolic tumour volume, in advanced or metastatic non-small cell lung cancer treated with first-line pembrolizumab. Ann Nucl Med. 2022 Mar;36(3):224-234. [IF = 2.668].
